Migraine  ||| S:0 E:9 ||| NNP
and  ||| S:9 E:13 ||| CC
central  ||| S:13 E:21 ||| JJ
sensitization ||| S:21 E:34 ||| NN
:  ||| S:34 E:36 ||| :
clinical  ||| S:36 E:45 ||| JJ
features ||| S:45 E:53 ||| NNS
,  ||| S:53 E:55 ||| ,
main  ||| S:55 E:60 ||| JJ
comorbidities  ||| S:60 E:74 ||| NN
and  ||| S:74 E:78 ||| CC
therapeutic  ||| S:78 E:90 ||| JJ
perspectives  ||| S:90 E:103 ||| JJ
BACKGROUND  ||| S:103 E:114 ||| NNP
Migraine  ||| S:114 E:123 ||| NNP
is  ||| S:123 E:126 ||| VBZ
a  ||| S:126 E:128 ||| DT
disorder  ||| S:128 E:137 ||| NN
of  ||| S:137 E:140 ||| IN
neuro-vascular  ||| S:140 E:155 ||| JJ
origin ||| S:155 E:161 ||| NN
,  ||| S:161 E:163 ||| ,
being  ||| S:163 E:169 ||| VBG
amongst  ||| S:169 E:177 ||| IN
the  ||| S:177 E:181 ||| DT
20  ||| S:181 E:184 ||| CD
most  ||| S:184 E:189 ||| RBS
disabling  ||| S:189 E:199 ||| JJ
disease ||| S:199 E:206 ||| NN
.  ||| S:206 E:208 ||| .
Migraine  ||| S:208 E:217 ||| JJ
attacks  ||| S:217 E:225 ||| NNS
are  ||| S:225 E:229 ||| VBP
characterized  ||| S:229 E:243 ||| VBN
by  ||| S:243 E:246 ||| IN
severe  ||| S:246 E:253 ||| JJ
throbbing  ||| S:253 E:263 ||| JJ
headache ||| S:263 E:271 ||| NN
,  ||| S:271 E:273 ||| ,
associated  ||| S:273 E:284 ||| VBN
to  ||| S:284 E:287 ||| TO
nausea ||| S:287 E:293 ||| VB
,  ||| S:293 E:295 ||| ,
vomiting ||| S:295 E:303 ||| NN
,  ||| S:303 E:305 ||| ,
photophobia ||| S:305 E:316 ||| NN
,  ||| S:316 E:318 ||| ,
and  ||| S:318 E:322 ||| CC
phonophobia ||| S:322 E:333 ||| NN
.  ||| S:333 E:335 ||| .
PATHOPHYSIOLOGY  ||| S:335 E:351 ||| NNP
AND  ||| S:351 E:355 ||| CC
ROLE  ||| S:355 E:360 ||| NNP
OF  ||| S:360 E:363 ||| IN
CENTRAL  ||| S:363 E:371 ||| NNP
SENSITIZATION  ||| S:371 E:385 ||| NNP
Abnormal  ||| S:385 E:394 ||| NNP
neuronal  ||| S:394 E:403 ||| NN
excitability  ||| S:403 E:416 ||| NNS
may  ||| S:416 E:420 ||| MD
subtend  ||| S:420 E:428 ||| VB
altered  ||| S:428 E:436 ||| VBN
processing  ||| S:436 E:447 ||| NN
of  ||| S:447 E:450 ||| IN
sensory  ||| S:450 E:458 ||| JJ
stimuli ||| S:458 E:465 ||| NNS
,  ||| S:465 E:467 ||| ,
leading  ||| S:467 E:475 ||| VBG
to  ||| S:475 E:478 ||| TO
cortical  ||| S:478 E:487 ||| VB
spreading  ||| S:487 E:497 ||| VBG
depression  ||| S:497 E:508 ||| NN
and  ||| S:508 E:512 ||| CC
trigeminal  ||| S:512 E:523 ||| JJ
activation ||| S:523 E:533 ||| NN
.  ||| S:533 E:535 ||| .
A  ||| S:535 E:537 ||| DT
dysfunction  ||| S:537 E:549 ||| NN
of  ||| S:549 E:552 ||| IN
pain  ||| S:552 E:557 ||| NN
modulation  ||| S:557 E:568 ||| NN
enhances  ||| S:568 E:577 ||| VBZ
central  ||| S:577 E:585 ||| JJ
sensitization  ||| S:585 E:599 ||| JJ
phenomena ||| S:599 E:608 ||| NNS
,  ||| S:608 E:610 ||| ,
contributing  ||| S:610 E:623 ||| VBG
to  ||| S:623 E:626 ||| TO
acute  ||| S:626 E:632 ||| JJ
allodynia  ||| S:632 E:642 ||| NN
and  ||| S:642 E:646 ||| CC
headache  ||| S:646 E:655 ||| JJ
persistence ||| S:655 E:666 ||| NN
.  ||| S:666 E:668 ||| .
The  ||| S:668 E:672 ||| DT
peculiarity  ||| S:672 E:684 ||| NN
of  ||| S:684 E:687 ||| IN
migraine  ||| S:687 E:696 ||| JJ
pain  ||| S:696 E:701 ||| NN
facilitates  ||| S:701 E:713 ||| VBD
the  ||| S:713 E:717 ||| DT
use  ||| S:717 E:721 ||| NN
of  ||| S:721 E:724 ||| IN
analgesics ||| S:724 E:734 ||| NN
,  ||| S:734 E:736 ||| ,
and  ||| S:736 E:740 ||| CC
causes  ||| S:740 E:747 ||| VBZ
an  ||| S:747 E:750 ||| DT
adjunctive  ||| S:750 E:761 ||| JJ
invalidating  ||| S:761 E:774 ||| JJ
tendency  ||| S:774 E:783 ||| NN
toward  ||| S:783 E:790 ||| IN
drug  ||| S:790 E:795 ||| NN
over-use ||| S:795 E:803 ||| NN
.  ||| S:803 E:805 ||| .
COMORBIDITY  ||| S:805 E:817 ||| NNP
Chronic  ||| S:817 E:825 ||| NNP
migraine  ||| S:825 E:834 ||| NN
patients  ||| S:834 E:843 ||| NNS
are  ||| S:843 E:847 ||| VBP
frequently  ||| S:847 E:858 ||| RB
affected  ||| S:858 E:867 ||| VBN
by  ||| S:867 E:870 ||| IN
diffuse  ||| S:870 E:878 ||| JJ
pain ||| S:878 E:882 ||| NN
,  ||| S:882 E:884 ||| ,
framed  ||| S:884 E:891 ||| VBN
in  ||| S:891 E:894 ||| IN
fibromyalgia  ||| S:894 E:907 ||| JJ
diagnosis ||| S:907 E:916 ||| NN
.  ||| S:916 E:918 ||| .
This  ||| S:918 E:923 ||| DT
comorbidity  ||| S:923 E:935 ||| NN
seems  ||| S:935 E:941 ||| VBZ
to  ||| S:941 E:944 ||| TO
be  ||| S:944 E:947 ||| VB
supported  ||| S:947 E:957 ||| VBN
by  ||| S:957 E:960 ||| IN
common  ||| S:960 E:967 ||| JJ
pathophysiological  ||| S:967 E:986 ||| JJ
mechanisms ||| S:986 E:996 ||| NNS
.  ||| S:996 E:998 ||| .
It  ||| S:998 E:1001 ||| PRP
may  ||| S:1001 E:1005 ||| MD
aggravate  ||| S:1005 E:1015 ||| VB
migraine  ||| S:1015 E:1024 ||| JJ
invalidity  ||| S:1024 E:1035 ||| NNS
being  ||| S:1035 E:1041 ||| VBG
worth  ||| S:1041 E:1047 ||| NN
of  ||| S:1047 E:1050 ||| IN
consideration  ||| S:1050 E:1064 ||| NN
for  ||| S:1064 E:1068 ||| IN
therapeutic  ||| S:1068 E:1080 ||| JJ
management ||| S:1080 E:1090 ||| NN
.  ||| S:1090 E:1092 ||| .
MIGRAINE  ||| S:1092 E:1101 ||| NNP
MANAGEMENT  ||| S:1101 E:1112 ||| NNP
Acute  ||| S:1112 E:1118 ||| NNP
and  ||| S:1118 E:1122 ||| CC
preventive  ||| S:1122 E:1133 ||| JJ
treatments  ||| S:1133 E:1144 ||| NNS
need  ||| S:1144 E:1149 ||| VBP
to  ||| S:1149 E:1152 ||| TO
be  ||| S:1152 E:1155 ||| VB
tailored  ||| S:1155 E:1164 ||| VBN
to  ||| S:1164 E:1167 ||| TO
single  ||| S:1167 E:1174 ||| JJ
cases ||| S:1174 E:1179 ||| NNS
.  ||| S:1179 E:1181 ||| .
Main  ||| S:1181 E:1186 ||| JJ
comorbidity  ||| S:1186 E:1198 ||| NN
and  ||| S:1198 E:1202 ||| CC
factors  ||| S:1202 E:1210 ||| NNS
facilitating  ||| S:1210 E:1223 ||| VBG
central  ||| S:1223 E:1231 ||| JJ
sensitization  ||| S:1231 E:1245 ||| NN
should  ||| S:1245 E:1252 ||| MD
be  ||| S:1252 E:1255 ||| VB
taken  ||| S:1255 E:1261 ||| VBN
into  ||| S:1261 E:1266 ||| IN
account ||| S:1266 E:1273 ||| NN
.  ||| S:1273 E:1275 ||| .
The  ||| S:1275 E:1279 ||| DT
management  ||| S:1279 E:1290 ||| NN
of  ||| S:1290 E:1293 ||| IN
migraine  ||| S:1293 E:1302 ||| JJ
patients  ||| S:1302 E:1311 ||| NNS
should  ||| S:1311 E:1318 ||| MD
include  ||| S:1318 E:1326 ||| VB
a  ||| S:1326 E:1328 ||| DT
link  ||| S:1328 E:1333 ||| NN
between  ||| S:1333 E:1341 ||| IN
headache  ||| S:1341 E:1350 ||| JJ
centers  ||| S:1350 E:1358 ||| NNS
and  ||| S:1358 E:1362 ||| CC
general  ||| S:1362 E:1370 ||| JJ
practitioner  ||| S:1370 E:1383 ||| NN
,  ||| S:1383 E:1385 ||| ,
in  ||| S:1385 E:1388 ||| IN
order  ||| S:1388 E:1394 ||| NN
to  ||| S:1394 E:1397 ||| TO
provide  ||| S:1397 E:1405 ||| VB
for  ||| S:1405 E:1409 ||| IN
a  ||| S:1409 E:1411 ||| DT
better  ||| S:1411 E:1418 ||| RBR
patient  ||| S:1418 E:1426 ||| JJ
information  ||| S:1426 E:1438 ||| NN
and  ||| S:1438 E:1442 ||| CC
treatment  ||| S:1442 E:1452 ||| NN
just  ||| S:1452 E:1457 ||| RB
at  ||| S:1457 E:1460 ||| IN
the  ||| S:1460 E:1464 ||| DT
onset  ||| S:1464 E:1470 ||| NN
of  ||| S:1470 E:1473 ||| IN
the  ||| S:1473 E:1477 ||| DT
disease ||| S:1477 E:1484 ||| NN
.  ||| S:1484 E:1486 ||| .
CONCLUSIONS  ||| S:1486 E:1498 ||| NNS
Despite  ||| S:1498 E:1506 ||| IN
its  ||| S:1506 E:1510 ||| PRP$
high  ||| S:1510 E:1515 ||| JJ
epidemiologic  ||| S:1515 E:1529 ||| JJ
impact ||| S:1529 E:1535 ||| NN
,  ||| S:1535 E:1537 ||| ,
migraine  ||| S:1537 E:1546 ||| NN
is  ||| S:1546 E:1549 ||| VBZ
frequently  ||| S:1549 E:1560 ||| RB
underestimated  ||| S:1560 E:1575 ||| VBN
and  ||| S:1575 E:1579 ||| CC
destined  ||| S:1579 E:1588 ||| VBN
to  ||| S:1588 E:1591 ||| TO
evolve  ||| S:1591 E:1598 ||| VB
into  ||| S:1598 E:1603 ||| IN
chronic  ||| S:1603 E:1611 ||| JJ
form  ||| S:1611 E:1616 ||| NN
and  ||| S:1616 E:1620 ||| CC
drugs  ||| S:1620 E:1626 ||| NNS
abuse ||| S:1626 E:1631 ||| NN
.  ||| S:1631 E:1633 ||| .
A  ||| S:1633 E:1635 ||| DT
more  ||| S:1635 E:1640 ||| RBR
focused  ||| S:1640 E:1648 ||| JJ
attention  ||| S:1648 E:1658 ||| NN
to  ||| S:1658 E:1661 ||| TO
factors  ||| S:1661 E:1669 ||| NNS
facilitating  ||| S:1669 E:1682 ||| VBG
central  ||| S:1682 E:1690 ||| JJ
sensitization  ||| S:1690 E:1704 ||| NN
and  ||| S:1704 E:1708 ||| CC
invalidating  ||| S:1708 E:1721 ||| JJ
comorbidities ||| S:1721 E:1734 ||| NN
,  ||| S:1734 E:1736 ||| ,
should  ||| S:1736 E:1743 ||| MD
reduce  ||| S:1743 E:1750 ||| VB
the  ||| S:1750 E:1754 ||| DT
global  ||| S:1754 E:1761 ||| JJ
burden  ||| S:1761 E:1768 ||| NN
of  ||| S:1768 E:1771 ||| IN
the  ||| S:1771 E:1775 ||| DT
disease ||| S:1775 E:1782 ||| NN
.  ||| S:1782 E:1784 ||| .
